Skip to main content
Erschienen in: Annals of Surgical Oncology 7/2016

08.03.2016 | Reconstructive Oncology

A Prospective Study on Skin-Sparing Mastectomy for Immediate Breast Reconstruction with Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy in Invasive Breast Carcinoma

verfasst von: Cécile Zinzindohoué, MD, Pierre Bertrand, MD, Aude Michel, PhD, Emilie Monrigal, MD, Bernard Miramand, MD, Nicolas Sterckers, MD, Christelle Faure, MD, Hélène Charitansky, MD, Marian Gutowski, MD, Monique Cohen, MD, Gilles Houvenaeghel, MD, PhD, Frederic Trentini, MD, Pedro Raro, MD, Jean-Pierre Daures, MD, PhD, Sandy Lacombe, MA

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Skin-sparing mastectomy (SSM) with immediate breast reconstruction (IBR) is increasingly used in invasive breast cancer. However, adjuvant chemotherapy (CT) and radiotherapy (RT) can increase the rate of local complications.

Objective

The aim of this study was to assess the morbidity of SSM–IBR after neoadjuvant CT and RT.

Methods

A French prospective pilot study of women aged 18–75 years with invasive breast cancer requiring mastectomy after CT and RT. Reconstruction was performed using autologous latissimus dorsi flap with or without prosthesis. The primary endpoint was the skin necrosis rate within 6 months, while secondary endpoints included pathological complete response rate (pCR) and global morbidity.

Results

Among 94 patients included in this study, 83 were analyzed (mean age 45.2 ± 9.5 years, T1 23.6 %, T2 55.6 %, T3 18.1 %). All but one patient received anthracyclines and taxanes, and all patients received RT (49.3 ± 5.2 Gy) before SSM–IBR. Prostheses were used for IBR in 32 patients (mean volume 256 ± 73 mm3). Five patients had necrosis (≤2 cm2, 2–10 cm2 and >10 cm2, in three, one, and one cases, respectively), and they all recovered without revision surgery. Among 50 patients who underwent upfront mastectomy, 36 % achieved pCR.

Conclusions

SSM–IBR performed after CT and RT is safe, with an acceptable local morbidity rate. Long-term data are needed to evaluate recurrence rates.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Heneghan HM, Prichard RS, Lyons R, et al. Quality of life after immediate breast reconstruction and skin-sparing mastectomy: a comparison with patients undergoing breast conserving surgery. Eur J Surg Oncol. 2011;37:937–943.CrossRefPubMed Heneghan HM, Prichard RS, Lyons R, et al. Quality of life after immediate breast reconstruction and skin-sparing mastectomy: a comparison with patients undergoing breast conserving surgery. Eur J Surg Oncol. 2011;37:937–943.CrossRefPubMed
3.
Zurück zum Zitat Carlson GW, Page A, Johnson E, et al. Local recurrence of ductal carcinoma in situ after skin-sparing mastectomy. J Am Coll Surg. 2007;204:1074–1078; discussion 1078–1080CrossRefPubMed Carlson GW, Page A, Johnson E, et al. Local recurrence of ductal carcinoma in situ after skin-sparing mastectomy. J Am Coll Surg. 2007;204:1074–1078; discussion 1078–1080CrossRefPubMed
4.
Zurück zum Zitat Carlson GW, Bostwick J 3rd, Styblo TM, et al. Skin-sparing mastectomy. Oncologic and reconstructive considerations. Ann Surg. 1997;225:570–575; discussion 575–578.PubMed Carlson GW, Bostwick J 3rd, Styblo TM, et al. Skin-sparing mastectomy. Oncologic and reconstructive considerations. Ann Surg. 1997;225:570–575; discussion 575–578.PubMed
5.
Zurück zum Zitat Carlson GW, Losken A, Moore B, et al. Results of immediate breast reconstruction after skin-sparing mastectomy. Ann Plast Surg. 2001;46:222–228.CrossRefPubMed Carlson GW, Losken A, Moore B, et al. Results of immediate breast reconstruction after skin-sparing mastectomy. Ann Plast Surg. 2001;46:222–228.CrossRefPubMed
6.
Zurück zum Zitat Downes KJ, Glatt BS, Kanchwala SK, et al. Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer. 2005;103:906–913.CrossRefPubMed Downes KJ, Glatt BS, Kanchwala SK, et al. Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer. 2005;103:906–913.CrossRefPubMed
7.
Zurück zum Zitat Greenway RM, Schlossberg L, Dooley WC. Fifteen-year series of skin-sparing mastectomy for stage 0 to 2 breast cancer. Am J Surg. 2005;190:918–922.CrossRefPubMed Greenway RM, Schlossberg L, Dooley WC. Fifteen-year series of skin-sparing mastectomy for stage 0 to 2 breast cancer. Am J Surg. 2005;190:918–922.CrossRefPubMed
8.
Zurück zum Zitat Meretoja TJ, von Smitten KA, Leidenius MH, et al. Local recurrence of stage 1 and 2 breast cancer after skin-sparing mastectomy and immediate breast reconstruction in a 15-year series. Eur J Surg Oncol. 2007;33:1142–1145.CrossRefPubMed Meretoja TJ, von Smitten KA, Leidenius MH, et al. Local recurrence of stage 1 and 2 breast cancer after skin-sparing mastectomy and immediate breast reconstruction in a 15-year series. Eur J Surg Oncol. 2007;33:1142–1145.CrossRefPubMed
9.
Zurück zum Zitat Patterson SG, Teller P, Iyengar R, et al. Locoregional recurrence after mastectomy with immediate transverse rectus abdominis myocutaneous (TRAM) flap reconstruction. Ann Surg Oncol. 2012;19:2679–2684.CrossRefPubMed Patterson SG, Teller P, Iyengar R, et al. Locoregional recurrence after mastectomy with immediate transverse rectus abdominis myocutaneous (TRAM) flap reconstruction. Ann Surg Oncol. 2012;19:2679–2684.CrossRefPubMed
10.
Zurück zum Zitat Romics L Jr, Chew BK, Weiler-Mithoff E, et al. Ten-year follow-up of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg. 2012;99:799–806.CrossRefPubMed Romics L Jr, Chew BK, Weiler-Mithoff E, et al. Ten-year follow-up of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg. 2012;99:799–806.CrossRefPubMed
11.
Zurück zum Zitat Rancati A, Soderini A, Dorr J, et al. One-step breast reconstruction with polyurethane-covered implants after skin-sparing mastectomy. J Plast Reconstr Aesthet Surg. 2013;66:1671–1675.CrossRefPubMed Rancati A, Soderini A, Dorr J, et al. One-step breast reconstruction with polyurethane-covered implants after skin-sparing mastectomy. J Plast Reconstr Aesthet Surg. 2013;66:1671–1675.CrossRefPubMed
12.
Zurück zum Zitat Kronowitz SJ, Robb GL. Breast reconstruction with postmastectomy radiation therapy: current issues. Plast Reconstr Surg. 2004;114:950–960.CrossRefPubMed Kronowitz SJ, Robb GL. Breast reconstruction with postmastectomy radiation therapy: current issues. Plast Reconstr Surg. 2004;114:950–960.CrossRefPubMed
13.
Zurück zum Zitat Motwani SB, Strom EA, Schechter NR, et al. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:76–82.CrossRefPubMed Motwani SB, Strom EA, Schechter NR, et al. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:76–82.CrossRefPubMed
14.
Zurück zum Zitat Nahabedian MY, Momen B. The impact of breast reconstruction on the oncologic efficacy of radiation therapy: a retrospective analysis. Ann Plast Surg. 2008;60:244–250.CrossRefPubMed Nahabedian MY, Momen B. The impact of breast reconstruction on the oncologic efficacy of radiation therapy: a retrospective analysis. Ann Plast Surg. 2008;60:244–250.CrossRefPubMed
15.
Zurück zum Zitat Prabhu R, Godette K, Carlson G, et al. The impact of skin-sparing mastectomy with immediate reconstruction in patients with Stage III breast cancer treated with neoadjuvant chemotherapy and postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2012;82:e587–593.CrossRefPubMed Prabhu R, Godette K, Carlson G, et al. The impact of skin-sparing mastectomy with immediate reconstruction in patients with Stage III breast cancer treated with neoadjuvant chemotherapy and postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2012;82:e587–593.CrossRefPubMed
16.
Zurück zum Zitat Rey P, Martinelli G, Petit JY, et al. Immediate breast reconstruction and high-dose chemotherapy. Ann Plast Surg. 2005;55:250–254.CrossRefPubMed Rey P, Martinelli G, Petit JY, et al. Immediate breast reconstruction and high-dose chemotherapy. Ann Plast Surg. 2005;55:250–254.CrossRefPubMed
17.
Zurück zum Zitat Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009;27:2474–2481.CrossRefPubMed Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009;27:2474–2481.CrossRefPubMed
18.
Zurück zum Zitat Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–785.CrossRefPubMed Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–785.CrossRefPubMed
19.
Zurück zum Zitat Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi7–23.CrossRefPubMed Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi7–23.CrossRefPubMed
20.
Zurück zum Zitat Monrigal E, Dauplat J, Gimbergues P, et al. Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy. A new option for patients with operable invasive breast cancer. Results of a 20 years single institution study. Eur J Surg Oncol. 2011;37:864–870.CrossRefPubMed Monrigal E, Dauplat J, Gimbergues P, et al. Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy. A new option for patients with operable invasive breast cancer. Results of a 20 years single institution study. Eur J Surg Oncol. 2011;37:864–870.CrossRefPubMed
21.
Zurück zum Zitat Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16:223–228.CrossRefPubMed Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16:223–228.CrossRefPubMed
22.
Zurück zum Zitat Peled AW, Foster RD, Stover AC, et al. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol. 2012;19:3402–3409.CrossRef Peled AW, Foster RD, Stover AC, et al. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol. 2012;19:3402–3409.CrossRef
23.
Zurück zum Zitat Petersen A, Eftekhari AL, Damsgaard TE. Immediate breast reconstruction: a retrospective study with emphasis on complications and risk factors. J Plast Surg Hand Surg 2012;46:344–348.CrossRefPubMed Petersen A, Eftekhari AL, Damsgaard TE. Immediate breast reconstruction: a retrospective study with emphasis on complications and risk factors. J Plast Surg Hand Surg 2012;46:344–348.CrossRefPubMed
24.
Zurück zum Zitat Kim Z, Kang SG, Roh JH, et al. Skin-sparing mastectomy and immediate latissimus dorsi flap reconstruction: a retrospective analysis of the surgical and patient-reported outcomes. World J Surg Oncol. 2012;10:259.CrossRefPubMedPubMedCentral Kim Z, Kang SG, Roh JH, et al. Skin-sparing mastectomy and immediate latissimus dorsi flap reconstruction: a retrospective analysis of the surgical and patient-reported outcomes. World J Surg Oncol. 2012;10:259.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Ho AL, Tyldesley S, Macadam SA, Lennox PA. Skin-sparing mastectomy and immediate autologous breast reconstruction in locally advanced breast cancer patients: a UBC perspective. Ann Surg Oncol. 2012;19:892–900.CrossRefPubMed Ho AL, Tyldesley S, Macadam SA, Lennox PA. Skin-sparing mastectomy and immediate autologous breast reconstruction in locally advanced breast cancer patients: a UBC perspective. Ann Surg Oncol. 2012;19:892–900.CrossRefPubMed
26.
Zurück zum Zitat Giacalone PL, Rathat G, Daures JP, et al. New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study. Breast Cancer Res Treat. 2010;122:439–451.CrossRefPubMed Giacalone PL, Rathat G, Daures JP, et al. New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study. Breast Cancer Res Treat. 2010;122:439–451.CrossRefPubMed
27.
Zurück zum Zitat Delbaere M, Delaporte T, Toussoun G, Delay E. Skin-sparing mastectomies: how to avoid skin necrosis? [in French]. Ann Chir Plast Esthet. 2008;53:208–225.CrossRefPubMed Delbaere M, Delaporte T, Toussoun G, Delay E. Skin-sparing mastectomies: how to avoid skin necrosis? [in French]. Ann Chir Plast Esthet. 2008;53:208–225.CrossRefPubMed
28.
Zurück zum Zitat Kroll SS, Schusterman MA, Reece GP, et al. Breast reconstruction with myocutaneous flaps in previously irradiated patients. Plast Reconstr Surg. 1994;93:460–469; discussion 470–461.CrossRefPubMed Kroll SS, Schusterman MA, Reece GP, et al. Breast reconstruction with myocutaneous flaps in previously irradiated patients. Plast Reconstr Surg. 1994;93:460–469; discussion 470–461.CrossRefPubMed
29.
Zurück zum Zitat Christante D, Pommier SJ, Diggs BS, et al. Using complications associated with postmastectomy radiation and immediate breast reconstruction to improve surgical decision making. Arch Surg. 2010;145:873–878.CrossRefPubMed Christante D, Pommier SJ, Diggs BS, et al. Using complications associated with postmastectomy radiation and immediate breast reconstruction to improve surgical decision making. Arch Surg. 2010;145:873–878.CrossRefPubMed
30.
Zurück zum Zitat Sbitany H, Wang F, Peled AW, et al. Immediate implant-based breast reconstruction following total skin-sparing mastectomy: defining the risk of preoperative and postoperative radiation therapy for surgical outcomes. Plast Reconstr Surg. 2014;134:396–404.CrossRefPubMed Sbitany H, Wang F, Peled AW, et al. Immediate implant-based breast reconstruction following total skin-sparing mastectomy: defining the risk of preoperative and postoperative radiation therapy for surgical outcomes. Plast Reconstr Surg. 2014;134:396–404.CrossRefPubMed
31.
Zurück zum Zitat Berry T, Brooks S, Sydow N, et al. Complication rates of radiation on tissue expander and autologous tissue breast reconstruction. Ann Surg Oncol. 2010;17 Suppl 3:202–210.CrossRefPubMed Berry T, Brooks S, Sydow N, et al. Complication rates of radiation on tissue expander and autologous tissue breast reconstruction. Ann Surg Oncol. 2010;17 Suppl 3:202–210.CrossRefPubMed
32.
Zurück zum Zitat Tsoi B, Ziolkowski NI, Thoma A, et al. Safety of tissue expander/implant versus autologous abdominal tissue breast reconstruction in postmastectomy breast cancer patients: a systematic review and meta-analysis. Plast Reconstr Surg. 2014;133:234–249.CrossRefPubMed Tsoi B, Ziolkowski NI, Thoma A, et al. Safety of tissue expander/implant versus autologous abdominal tissue breast reconstruction in postmastectomy breast cancer patients: a systematic review and meta-analysis. Plast Reconstr Surg. 2014;133:234–249.CrossRefPubMed
33.
Zurück zum Zitat Aryus B, Audretsch W, Gogolin F, et al. Remission rates following preoperative chemotherapy and radiation therapy in patients with breast cancer. Strahlenther Onkol. 2000;176:411–415.CrossRefPubMed Aryus B, Audretsch W, Gogolin F, et al. Remission rates following preoperative chemotherapy and radiation therapy in patients with breast cancer. Strahlenther Onkol. 2000;176:411–415.CrossRefPubMed
34.
Zurück zum Zitat Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2015;22(4):1118–27.CrossRefPubMed Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2015;22(4):1118–27.CrossRefPubMed
35.
Zurück zum Zitat Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260:608-614; discussion 614–606.CrossRefPubMedPubMedCentral Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260:608-614; discussion 614–606.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Luangdilok S, Samarnthai N, Korphaisarn K. Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients. J Breast Cancer. 2014;17:376–385.CrossRefPubMedPubMedCentral Luangdilok S, Samarnthai N, Korphaisarn K. Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients. J Breast Cancer. 2014;17:376–385.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Mombelli S, Kwiatkowski F, Abrial C, et al. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease. Oncology. 2015;88(5):261–72.CrossRefPubMed Mombelli S, Kwiatkowski F, Abrial C, et al. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease. Oncology. 2015;88(5):261–72.CrossRefPubMed
38.
Zurück zum Zitat Tan QX, Qin QH, Yang WP, et al. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol. 2014;7:6862–6870.PubMedPubMedCentral Tan QX, Qin QH, Yang WP, et al. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol. 2014;7:6862–6870.PubMedPubMedCentral
39.
Zurück zum Zitat Kaidar-Person O, Kuten A, Belkacemi Y; AROME. Primary systemic therapy and whole breast irradiation for locally advanced breast cancer: a systematic review. Crit Rev Oncol Hematol. 2014;92:143–152.CrossRefPubMed Kaidar-Person O, Kuten A, Belkacemi Y; AROME. Primary systemic therapy and whole breast irradiation for locally advanced breast cancer: a systematic review. Crit Rev Oncol Hematol. 2014;92:143–152.CrossRefPubMed
40.
Zurück zum Zitat Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019–2027.CrossRefPubMed Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019–2027.CrossRefPubMed
Metadaten
Titel
A Prospective Study on Skin-Sparing Mastectomy for Immediate Breast Reconstruction with Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy in Invasive Breast Carcinoma
verfasst von
Cécile Zinzindohoué, MD
Pierre Bertrand, MD
Aude Michel, PhD
Emilie Monrigal, MD
Bernard Miramand, MD
Nicolas Sterckers, MD
Christelle Faure, MD
Hélène Charitansky, MD
Marian Gutowski, MD
Monique Cohen, MD
Gilles Houvenaeghel, MD, PhD
Frederic Trentini, MD
Pedro Raro, MD
Jean-Pierre Daures, MD, PhD
Sandy Lacombe, MA
Publikationsdatum
08.03.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5146-y

Weitere Artikel der Ausgabe 7/2016

Annals of Surgical Oncology 7/2016 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.